These observations supported our hypothesis that treating 4T1 tumor cells with BSA-FITC-Man@Mn2+-Ft@Lap could substantially enhance their immunogenicity through releasing abundant DAMPs, which may facilitate the subsequent activation of tumor-specific CD4 and CD8 T cells for enhancing the antitumor immune response. This evidence concerns the gene CD8A and neoplasm.